Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Participants needed: 112
Trial details
Phase: Phase 1, Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: Perspective TherapeuticsUpdated: Jul 6, 2026Locations: 11
Eligibility criteria

Aged ≥ 18 years [+6]

Known hypersensitivity to the active agent or any of the excipients [+12]

Read more
Status: Recruiting

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.

Participants needed: 300
Trial details
Phase: Phase 1, Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: Perspective TherapeuticsUpdated: Jun 10, 2026Locations: 13
Eligibility criteria

Ability to understand and willingness to provide informed consent, willingness t... [+12]

Active secondary malignancy [+16]

Read more
Status: Recruiting

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

Participants needed: 300
Trial details
Phase: Phase 1, Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: Perspective TherapeuticsUpdated: May 14, 2026Locations: 19
Eligibility criteria

Adult (ages ≥18) PRRT-naïve subjects with NETs or meningioma by local pathology. [+16]

Known hypersensitivity to SSA, SSTR imaging agents or any of the excipients of [... [+19]

Read more